Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients-Reference-Cited by-同舟云学术

Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients

Published:2020-02 Issue:1 Volume:3 Page:119-127
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Efstathiou Eleni,Titus Mark,Wen Sijin,Troncoso Patricia,Hoang Anh,Corn Paul,Prokhorova Ina,Araujo John,Dmuchowski Carl,Melhem-Bertrandt Amal,Patil Shiva,Logothetis Christopher J.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference21 articles.

1. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

2. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

3. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study;Scher;Lancet,2010

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer;Molecular Biology Reports;2024-01-28

2. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial);Journal of Clinical Oncology;2023-06-20

3. Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience;Anticancer Research;2022-12-30

4. Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer;Aging;2022-12-19

5. Low-Dose Enzalutamide in Metastatic Prostate Cancer—Longevity Over Conventional Survival Analysis;Clinical Genitourinary Cancer;2022-12